Congratulations to IGCS Global Curriculum Graduates!

Congratulations to the first three fellows completing their two-year training and final examinations through the IGCS Gynecologic Oncology Global Curriculum & Mentorship Program!

Dr. Benjamin Elly Odongo
Moi University Hospital, Kenya
Dr. Jerome Katumba
Uganda Cancer Institute
Dr. Marian Nabwire
Uganda Cancer Institute

The Global Curriculum was established in 2017 under the leadership of then-IGCS President, Michael Quinn. It is a comprehensive education, training, and mentorship program designed for regions around the world that do not currently have formal training in gynecologic oncology. There are now 12 training sites utilizing the IGCS program under the leadership and guidance of Drs. Tom Randall and Linus Chuang.

The program at Moi University in Kenya has been in place for about 10 years, producing a number of gynecologic cancer specialists practicing in Kenya and Uganda. Dr. Benjamin Elly Odongo is the first to complete the Moi University program with the IGCS Global Curriculum in place. The program at the Uganda Cancer Institute was initiated more recently in 2017, utilizing the IGCS Global Curriculum from the start. Notably, Drs. Mariam Nabwire and Jerome Katumba are the first gynecologic oncologists to be trained locally in Uganda.

Instrumental to the program’s success is the hard work of the fellows, local faculty and administrators at each facility who are committed to implementing the curriculum and working to ensure its sustainability over time. We also acknowledge the dedication and support of the international mentors from established institutions and faculty contributors who participate in monthly Project ECHO virtual tumor board video conferences. Finally, we’d like to thank Dr. Allan Covens for his efforts as Chair of the Final Examination Committee.

To learn more about the program, please download the 2019 Annual Report.

Those who would like to learn more about how to contribute to the mentorship and training aspects of this program, please email

Dr. Benjamin Elly Odongo
Moi University Hospital, Kenya
Fellowship Training Completed: 2019

“The IGCS Fellowship, especially the time spent to prepare for the ECHO tumor boards made me realize that no matter how busy I thought I was, I had to find time for reading, or surrender myself to self-chosen ignorance.

Having local mentors made me understand that there are abilities within us which have not yet been developed and can be developed further particularly the skills to manage patients with gynecological malignancies locally, the resource limitations notwithstanding.

The international mentors and the time spent at The University of Toronto led me to the discovery of the fundamental fact that we are continually learning new things and that the problems which perplex us in our part of the world can be solved through leadership, research and commitment. I am therefore proceeding to advocate for implementation of cancer prevention strategies, support efforts towards improving the capacity to make accurate cancer diagnosis, provision of treatment including palliative and end of life care.”

See more about the program in Kenya.

Dr. Jerome Katumba
Uganda Cancer Institute
Fellowship Training Completed: 2019

“I am extremely excited by the great achievement of completing the IGCS Fellowship and becoming one of the first gynecologic oncologists locally trained in Uganda. This fellowship has enriched my knowledge and skills in the field of gynecologic oncology and has completely changed my approach and practice in the management of patients.

I extend my sincere gratitude to my local and external mentors who toiled to impart us with the knowledge and skills during the training. I am also beholden by the hospitality and shadowing experience I enjoyed from the staff of the University of California San Francisco Hospital, North Carolina University Hospital and Duke University Hospital.

Bravo IGCS Fellowship Team! Keep the candle burning.”

Dr. Marian Nabwire
Uganda Cancer Institute
Fellowship Training Completed: 2019

“The cogitation to initiate the gynecologic oncology fellowship training program in Uganda is a great turning point. The extensive support provided by the IGCS, our external mentors, and the local mentors has led to a successful fellowship program.

I am honored to be one of the first two gynecologic oncologists trained in Uganda. We plan to set up the Uganda gynecologic oncology association to ensure quality and sustainability of gynecologic oncology services in Uganda and Africa at large.”

See more about the program in Uganda.

Thoughts from Mentors & Leaders

“Congratulations to the first three international fellows to pass the final exam for the IGCS Gynecologic Oncology Global Curriculum and Mentorship Program. We are incredibly proud of our fellows and want to thank our local and international mentors for their dedication and support. Together they are changing the care and outcomes of women with gynecologic cancers around the globe.”

– Dr. Kathleen Schmeler (MD Anderson Cancer Center)
IGCS Mentorship & Training Committee Chair & International Mentor for the Mozambique Fellowship Program

“This is a really important day for IGCS. The implications for the care of women from disadvantaged backgrounds are enormous and truly reflect our mission to improve outcomes by teaching and training. Our challenge now is to get the resources to expand the program and to ensure that our new international specialists continue to be supported. Sincere congratulations to all concerned.”

-Dr. Michael Quinn
IGCS Past President and Founder of the Global Curriculum & Mentorship Program

“I am immensely proud of Mariam Nabwire and Jerome Katumba for their achievement in successfully completing their fellowship. They are the first two fellows to graduate from the Uganda program. Their success embodies all the efforts from the current local faculty including Drs. Anthony Okoth, Jane Namugga, Carolyn Nakisige, Judith Ajeani, Miriam Nakalembe; and from the administration including Drs. Jackson Orem, Annettee Nakimuli, and Nixon Niyonzima.

The initial vision for gynecologic oncology sub-specialization came from the prior Head of Department for Obstetrics and Gynecology, Dr. Josaphat Byamugisha, almost 10 years ago. With his leadership combined with Dr. Jackson Orem, the Director of the Uganda Cancer Institute, and leadership from Makerere University, Mulago Hospital, and the Ministry of Health, the gynecologic oncology fellowship in Uganda began in October 2017.

The partnership with IGCS strengthened the curriculum and processes to achieve excellence in the quality of training. With IGCS funding support, Jerome and Mariam were able to complete an 8 week observership in the United States that they both found very meaningful for their training. In addition, the support from other passionate global educators from IGCS has been very rewarding to me.

I am very grateful for the commitment of all the external mentors, especially Dr. Stefanie Ueda. With her experience, I learned how to navigate mentorship and leadership in a challenging setting with many stakeholders involved. I owe many thanks to Duke, especially Dr. Andrew Berchuck, who supported and believed in me to make a difference. Finally, I am grateful to the women in Uganda to trust their care in us as we continue to do our best to improve their gynecologic oncology outcomes.”

-Dr. Paula Lee (Duke University Hospital)
International Mentor for the Uganda Fellowship Program

“On behalf of myself and Dr. Barry Rosen, and the local supervisors Drs. Omenge, Tonui, and Itsura, we congratulate Dr. Elly Benjamin on his successful completion of the IGCS Global Curriculum in Gynecologic Oncology. He is a special and unique individual. We are proud of both his accomplishments, and the tremendous success of our program at Moi University in Eldoret, Kenya.

Our program has been running for approximately 10 yrs, and has produced a number of gynecologic oncologists currently practicing in Kenya and Uganda. Dr. Benjamin’s accomplishment as one of the first to formally pass the IGCS training program in gynecologic oncology highlights his and our success, and is inspiring for all training programs and individuals working in low resource countries.

The collaborative efforts of the IGCS team, combined with the dedication of the international mentors, local supervisors, in addition to all the individuals participating on the monthly ECHO calls embodies the value and importance this initiative is to so many.

We hope Elly is just one of many such individuals to successfully complete this training program in the future.”

-Dr. Allan Covens (University of Toronto and Sunnybrook Health Sciences Center)
International Mentor for the Moi University Fellowship Program

Membership Milestone – 3200 Members!

President’s Perspective

Dear Colleagues,

As I reflect on the past three years, our society was made up of about 900 members, mostly from the United States, Europe, and Asia.

Today, IGCS has transformed into a truly global organization with over 3200 members in 115 countries across the globe.

The IGCS Council, along with our new administrative structure led by our CEO, Mary Eiken, set goals to grow our membership and balance the representation between high-, middle-, and low-income countries.

IGCS began engaging members in new ways to enhance our programs, with a focus on mentorship and training, online education, and outreach to improve the gynecologic cancer care worldwide. She guided Council to re-imagine our membership strategy, utilizing the strength of our collaborative relationships with key leaders and gynecologic oncology groups around the world.

Due to these efforts over the past three years, IGCS’s global presence has spread – especially in Latin America, Central and Eastern Asia, and Africa.
The most recent growth that has pushed us over the threshold of 3000 came from the United States, Canada, Vietnam, and Bangladesh.
Much of this growth has emanated from our Strategic Alliance Partner Program in which we have formed mutually beneficial alliances with regional and international gynecologic oncology groups whose objectives are consistent and aligned with our own.

The partnerships unite us, allowing for closer dialogue, idea sharing, and a forum for information and collaboration in finding solutions to the many issues that face us all.

They also allow us to align our voices in the global arena in many ways, including our interactions with International Federation of Gynecology and Obstetrics (FIGO), The World Health Organization (WHO) and others. The voice is more powerful and impactful when we stand together.

I must express my gratitude to all our partners for their willingness to join us and work together to achieve our common goals. The IGCS motto has always been “to unite the globe in the fight against gynecologic cancers.” From my perspective, we operate by this guiding principle and I am honored that our members, supporters, and partners place their trust in us to be the global voice of gynecologic cancers.

IGCS is grateful for those who have been loyal, long-standing members of the IGCS and those who are new to IGCS residing in high-income regions of the world. These members provide such a wealth of knowledge, passion and desire to make a difference. IGCS so appreciates their efforts in making all of our programs successful and impactful.

So many of you regularly reach out and ask, “How can I get involved and help?” Those who are interested in becoming involved – we can always use multidisciplinary volunteers to serve as expert contributors on Project ECHO virtual tumor board calls. Monthly video conferences are conducted with 17 different sites. If you’d like to volunteer, please complete this brief online form so we can assess your availability for the calls.

For the nonmember friends of IGCS, we hope you will consider membership in 2020. We continue to place a major focus on our expanding repertoire of membership benefits, programs, and opportunities for involvement. There truly are many reasons to be a part of the IGCS.

In closing, one thing is for certain, we would not be celebrating this membership milestone without the efforts of our dedicated team of volunteers. Leaders on the IGCS Council, committees and work groups are engaged every day and work tirelessly to improve the lives of women affected by gynecologic cancers worldwide. We have accomplished so much together already, and I look forward to the future with optimism.


Roberto Angioli, MD
2018-2020 IGCS President

Education Highlight: IGCS 2019 Webcasts

Education Highlight: IGCS 2019 Annual Global Meeting Webcasts
Over 60 recorded presentations (webcasts) from the 2019 IGCS Annual Global Meeting held in Rio de Janeiro September 19-21, 2019 are now available.

The IGCS 2019 scientific program included live surgical videos with commentary, pro/con debates, case discussions with expert panels, region-specific sessions, and much more.

All of this excellent educational content is publicly available on the IGCS website through January 1, 2020.

IGCS Members will have continued access to these recordings and more through the IGCS online Education Portal. Presentations are being categorized by topic will be uploaded to our member’s Education Portal in the next several weeks

Not a member? Join today to access our entire library of educational videos and resources. See more Education Highlights.


IJGC: Latest Content

November 2019 Issue

See the latest articles, videos and podcasts.

Volume 29 Issue 9 Table of Contents

The International Journal of Gynecological Cancer (IJGC) is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. Its content is read by gynecologists, medical oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a special interest in gynecological oncology. IJGC emphasizes a multidisciplinary approach and includes original research, reviews, and video articles.



Minimally invasive interval cytoreductive surgery: it’s time for a randomized trial 
Alexander Melamed, Jose Alejandro Rauh-Hain


Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy
Jeremie Abitbol, Walter Gotlieb, Ziggy Zeng, Agnihotram Ramanakumar, Roy Kessous, Liron Kogan, Valerie Pare-Miron, Marcelo Rombaldi, Shannon Salvador, Beste Kucukyazici, Sonya Brin, Jeffrey How, Susie Lau


Can somatic BRCA2 status solve a case of olaparib monotherapy resistance? 
Antonella Pietragalla, Angelo Minucci, Claudia Marchetti, Giovanni Scambia, Anna Fagotti


Connecting frontline providers in Africa with distant experts to improve patients’ outcomes through Project ECHO: a successful experience in Cameroon
Joel Fokom Domgue, Ellen Baker, Florence Manjuh, Melissa Lopez, Thomas Welty, Kathleen M Schmeler


Laparoscopic intra-operative ultrasound-guided bilateral salpingo-oophorectomy in a BRCA2 mutated patient 
Matteo Bruno, Ilaria De Blasis, Benito Marinucci, Antonia Carla Testa, Giovanni Scambia, Anna Fagotti

Sentinel lymph node in apparent early ovarian cancer: open technique 
Victor Lago, Pilar Bello, María Tiermes Marina Martín, Beatriz Montero, Pablo Padilla-Iserte, Susana Lopez, Luis Matute, Santiago Domingo

Education Highlight: IGCS’s First Webinar Recording

In this month’s IGCS Education Highlight, we bring you recordings from our live-streaming webinar: Gynecologic Cancer Update.

This was the first event of its kind hosted by the IGCS.

Dr. R. Wendel Naumann (USA) hosted the event on Sept 6, 2019 at Levine Cancer Institute in Charlotte, NC. Several expert speakers presented the most recent updates on various topics related to gynecologic cancers.

The live event was a great success with nearly 200 participants joining from 54 countries.

If you missed the live event, you can view all the recorded presentations on the IGCS website and download select slides which have been made public for both IGCS members and non-members.





Gynecologic Oncology News & Updates

A compilation of articles, news, study results and other updates in the field of gynecologic oncology.

Entries with titles highlighted in red may be of particular interest to survivors, caregivers or the general public.

PARP Inhibitors Center Stage for Ovarian Cancer
October 7, 2019: Medscape – “I think the main message is that more women can benefit from having a PARP inhibitor in the first-line setting as maintenance treatment beyond those women with the BRCA mutation.” Read more.

A promising treatment for ovarian cancer
October 7, 2019: Kaiser Permanente – 5 Questions for…Dr. Michael A. Bookman, co-leader of a clinical trial that could provide an important new treatment option for women with advanced gynecological cancers. Read more.

Experts in Oncology Highlight Key Abstracts Presented at the 2019 ESMO Congress
October 7, 2019: Targeted Oncology – Following the 2019 ESMO Congress, experts across various fields highlighted some next steps and how these treatment options will improve the treatment landscape for patients with ovarian, lung, breast, GI, or GU cancers. Read more.

New Evidence for Hyperbaric Therapy for Late Radiation Cystitis
October 4, 2019: Cancer Network – Hyperbaric oxygen therapy can relieve symptoms of late radiation cystitis in patients who underwent radiotherapy of the pelvic region for prostate cancer. Read more.

How three women trusted their instincts and discovered they had cancer
October 3, 2019: ABC News – By the time Sandra Hoehler was diagnosed with cancer, it was as much a moment of relief as one of fear. Read more.

What You Need to Know About Preventing Gynecologic Cancers
October 3, 2019: CURE – Knowing your family history is the first preventative step any woman can take to avoid a diagnosis of ovarian cancer. Read More.

Avelumab active in mismatch repair-deficient endometrial cancer
October 3, 2019: Healio – Avelumab induced promising activity among women with mismatch repair-deficient endometrial cancer regardless of PD-L1 status. Read more.

Patients Die While Docs on Hold
October 3,2019: Medpage Today – It shouldn’t take medical practitioners hours by phone to reach a knowledgeable person who can fairly review an appeal about a patient’s coverage. And, for gynecological cancers, that review should be made by oncologists familiar with cancer treatments, not by the pharmacist who happens to be on call that day. Read more.

More accurate diagnosis for rare ovarian cancer type
October 3, 2019: Medical XPress – The researchers found that the new biomarker—when it’s used in combination with another, established marker—increased the accuracy of the diagnosis. Read more.

How the new test for cervical cancer works – and why you should have it
October 2, 2019: The Sydney Morning Herald – What testing do you need to get done to avoid cervical cancer? Can treatment ruin your sex life? And what happens if the test shows that you have cancer? Read more,

Geography Determines Access to Palliative Care
October 2, 2019: Health Leaders – Access to and quality of hospital-based palliative care in the United States has more to do with geography than need, a new state-by-state report card finds. Read more.

Let’s Talk About Cancer Prevention and the Power of Support
October 2, 2019: Cure – “Most days, I feel empowered by the knowledge of my BRCA mutation. I encourage others to learn their family health history and to seek genetic counseling, if appropriate.” Read more.

Niraparib Shows “Impressive” Survival Improvements in Advanced Ovarian Cancer
October 2, 2019: Cancer Network – Maintenance therapy with niraparib (Zejula) showed a significant progression-free survival (PFS) benefit for patients with newly diagnosed advanced ovarian cancer in the randomized phase 3 PRIMA trial, regardless of homologous recombination deficiency status. Read more.

Breast Cancer Death Rate Continues to Drop, But Black Women Have Far Higher Mortality Rates
October 2, 2019: Forbes – Between 2013 and 2017, the death rate from breast cancer was 40% higher in black women than in white women, despite a slightly smaller incidence of breast cancer in black women. Read more.

Rising Obesity and Declining Fertility Linked with Increasing Breast Cancer Cases in U.S
October 2, 2019: Newsweek – A decades-long decline in breast cancer deaths in the U.S. has started to slow, while diagnosed cases of the condition have increased slightly—a trend that scientists believe could be partly caused by the obesity epidemic and declining fertility. Read more.

Hysterectomy May Raise Depression and Anxiety Risk
October 1, 2019: New York Times – Women who have a hysterectomy may be at increased risk for depression and anxiety. Four to six percent of women will develop depression or anxiety. Read more.

Pressure BioSciences’ Proprietary PCT Platform Fills Pivotal Role for Tumor Analyses in Novel Workflow Presented at Leading Global Gynecologic Cancer Meeting
October 1, 2019: Global Newswire – Data from Analysis of Cancer Tissue Proteins Generated from Novel Workflow Could Lead to Improvement in the Clinical Management of Gynecological Cancers. Read more.

Novel immunotherapy combination could provide fresh hope for patients with cervical cancer
September 30, 2019: News Medical – This cohort paired nivolumab with ipilimumab for the treatment of patients with recurrent or metastatic cervical cancer, with or without prior systematic therapies, and irrespective of PD-L1 expression. Read more.

Trametinib Tx Shows Promise in Tough-to-Treat LGSOC
September 30, 2019: MedPage Today – Trametinib treatment was associated with better outcomes in women with recurrent or progressive low-grade serous ovarian or peritoneal cancer versus treatment with standard-of-care chemotherapy. Read more.

Nivolumab-ipilimumab combination benefits women with advanced cervical cancer
September 30, 2019: Healio – “This is the most exciting data we have ever seen [among women] with metastatic cervical cancer,” R. Wendel Naumann, MD, professor and associate director of gynecologic oncology at Levine Cancer Institute at Atrium Health. Read more.

‘I Beat a Rare Form of Ovarian Cancer Twice—But I’m Still Doing Chemo’
September 30, 2019: Yahoo – Rose Marie Jackey is sitting in her hospital bed at Mount Sinai Hospital in New York City awaiting her monthly chemotherapy infusion treatment she’s been getting each month for the past three years. Read more.

Fertility-Sparing Surgery Equally Effective as Radical Surgery in Early Stage Ovarian Cancer, Study Finds
September 30, 2019: Ovarian Cancer News Today – Surgical treatment aimed at preserving fertility is just as effective, in terms of survival, as more aggressive surgery in treating early-stage ovarian cancer. Read more.

Immunotherapy in combination points to paradigm shift in the treatment of cervical cancer
September 30, 2019: Medical Xpress – With an estimated 570,000 cases and 311,000 deaths in 2018 worldwide, cervical cancer currently ranks as the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women. Read more.

Trauma-Informed Care Emphasizes Healthcare as a Partnership
September 30, 2019: Medpage Today – With so many women experiencing trauma in their lifetime, clinicians should take a patient-centered approach to care. Read More.

Addition of M6620 to gemcitabine prolongs PFS in platinum-resistant ovarian cancer
September 29, 2019: Healio – “Platinum-resistant ovarian cancer is associated with poor prognosis and represents an important unmet medical need.” Read more.

Veliparib regimen extends PFS in newly diagnosed high-grade serous ovarian carcinoma
September 29, 2019: Healio – The addition of veliparib to frontline chemotherapy followed by maintenance with veliparib monotherapy significantly prolonged PFS among women with newly diagnosed, high-grade serous ovarian carcinoma. Read more.

Niraparib significantly extends PFS in newly diagnosed advanced ovarian cancer
September 28, 2019: Healio – Niraparib significantly extended PFS among women with newly diagnosed advanced ovarian cancer, according to results of the randomized phase 3 PRIMA study presented at European Society for Medical Oncology Congress. Read more.

Ovarian cancer: more women benefit from maintenance combined targeted therapy
September 28, 2019: European Society for Medical Oncology – New data shows the benefit of a more intensive maintenance regimen for ovarian cancer with the PARP inhibitor olaparib added to bevacizumab, in an all-comers population, with and without a BRCA mutation. Read more.

First-Line Combo Boosts PFS in Advanced Ovarian Cancer
September 28, 2019: Medpage Today -Dual maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) in women with newly diagnosed advanced ovarian cancer, as compared with single-agent bevacizumab. Read more.

Good News For Women With Newly-Diagnosed Ovarian Cancer
September 28, 2019: Survivor Net – A specific PARP inhibitor called Zejula more than doubled the amount of time that many women with ovarian cancer lived without their cancer getting worse. Read more.

Cediranib plus olaparib effective, safe for recurrent, platinum-resistant ovarian cancer
September 28, 2019: Healio – The combination of cediranib and olaparib appeared to be effective and safe for women with heavily pretreated, platinum-resistant ovarian cancer. Read more.

Results of the VELIA Trial in Ovarian Cancer
September 28, 2019: Targeted Oncology – Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the results of the phase III VELIA trial in patients with advanced ovarian cancer. See more.

PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients
September 27, 2019: News Wise – Study shows that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival (PFS) for patients with newly diagnosed, metastatic high-grade serous ovarian cancer. Read more.

What Women Should Know About the FDA’s Endometrial Cancer Combination Approval
September 23, 2019: CURE – Women with endometrial cancer that is not categorized as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who are not eligible for curative surgery or radiation, and whose disease has progressed after previous systemic therapy now have a new, and much needed, treatment option. Read more.

Nivolumab May Induce Promising Efficacy Outcomes in Certain Gynecologic Malignancies
September 23, 2019: Cancer Network – Treatment with nivolumab demonstrated promising efficacy results among patients with recurrent/metastatic cervical and vaginal or vulvar cancers. Read more.

Study Shows Niraparib Extends Time Without Symptoms, Toxicity in Ovarian Cancer
September 20, 2019: Oncology Nursing News – Treatment with niraparib (Zejula) improved survival and extended the time without symptoms or toxicity among patients with recurrent ovarian cancer, according to study results published in the Journal of Clinical Oncology. Read more.

Here’s Why Ovarian Cancer Is So Hard to Diagnose, According to a Doctor
September 20, 2019: Prevention – Ovarian cancer is often referred to as “the silent killer” for a good reason: It ranks as the fifth deadliest cancer among women. In fact, of the 22,530 women who will receive an ovarian cancer diagnosis each year, nearly 14,000 of them will die from it. Read more.

Can Recurrent Ovarian Cancer Patients Avoid Chemotherapy?
September 20, 2019: Cancer Network – The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. Read more.

Dr. Gunderson on the GOG-252 Trial in Advanced Ovarian Cancer
September 19, 2019: Onc Live – Camille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the phase III open-label GOG-252 trial (NCT01167712) in advanced ovarian cancer. See more.

Dr. Moore on Research Evaluating Repeat Exposure to PARP Inhibition in Ovarian Cancer
September 19, 2019: Onc Live – In the prospective phase II Evolve study, Stephanie Lheureux, MD, and her colleagues took women who had progressed on a prior PARP inhibitor and evaluated one of the reported mechanisms of acquired resistance to PARP with combination therapy. Read more.

Guest columnist: Writer shares ovarian cancer diagnosis, treatment
September 17, 2019: The State Journal – Quite honestly, I did not know much about this type of cancer when I first heard the term “ovarian” in November. Since that time, my knowledge about ovarian cancer has increased as I am now up close and personal with a Stage IV diagnosis. Read more.

My Surprising Experience with Ovarian Cancer
September 11, 2019: Thrive Global – This is my story with ovarian cancer and I share it in hopes of helping someone that experiences similar emotions, though not necessarily the same diagnosis or situation. Read more.

Scientists call for population-wide BRCA testing for higher risk group
September 11, 2019: Medical Xpress – Researchers are calling for population wide BRCA testing in the Jewish community after finding it to be more effective than current approaches, cost effective and had a high satisfaction rate with those undergoing testing. Read more.

Encouraging Responses Seen with TIL Therapy in Advanced Cervical Cancer
September 4, 2019: Targeted Oncology – Investigators set out to determine the safety and effectiveness of the TIL therapy in patients with advanced disease who have received at least one prior line of chemotherapy. Read more.

Surgeons remove 55-pound ovarian tumor from Russian patient, report says
August 28, 2019: Fox – A medical team in Russia has shared photos from a mind-boggling procedure last week that saw them remove a 55-pound tumor that had been growing in a patient’s pelvis. Read more.

Pain Associated With Quality of Life and Survival for Patients With Recurrent Ovarian Cancer
August 27, 2019: Oncology Nurse Advisor – For patients with recurrent ovarian cancer (OC), pain is associated with both quality of life (QOL) and overall survival. Read more.

Will advances in AI lead to more effective screening practices for ovarian cancer?
August 25, 2019: Healio – Screening techniques for ovarian cancer are nonexistent. Studies have looked at combinations of blood markers and ultrasounds, but they did not show a survival improvement. Ultimately, if a patient undergoes screening, it should lead to some improvement in outcome or prevention of the cancer altogether. Read more.

Remaining Ever Vigilant in Cancer Screening
August 20, 2019: CURE – Three years ago, I received a call from a geneticist explaining that, unfortunately, my blood sample showed that I had Lynch syndrome. Read more.

‘Why me? I had ovarian cancer at 14’
August 20, 2019: BBC News – When 14-year-old Kelliyah started experiencing severe abdominal pain, she initially blamed it on one too many fizzy drinks and a lack of exercise. She lived with the persistent symptoms for weeks before going to hospital. But once she did, doctors found a tumor the size of a pumpkin and, within 24 hours, Kelliyah was diagnosed with ovarian cancer. Doctors found a tumor weighing more than 5kg. Read more.

Nivolumab As Salvage Therapy Signals Response in Patients With Heavily Pretreated Gynecologic Cancers
August 19, 2019: Targeted Oncology – A retrospective study conducted at the Georgia Cancer Center in Augusta examined overall response and progression-free survival (PFS) in heavily pretreated patients with gynecologic malignancies who had received checkpoint inhibition therapy with nivolumab (Opdivo) in the salvage setting. Read more.

FDA announces international collaboration, approves pembrolizumab plus lenvatinib for endometrial cancer
September 17, 2019: Healio – The FDA, in conjunction with decisions by regulatory agencies in Australia and Canada, granted accelerated approval to pembrolizumab in combination with lenvatinib for the treatment of certain women with advanced endometrial carcinoma. Read more.

Expert Reviews Study Findings for Radical Hysterectomy in Cervical Cancer
September 11, 2019: Targeted Oncology – Sarah Ferguson, MD, discusses her experience being involved in a population-based study of women with cervical cancer treated with a radical hysterectomy. See More.

PTSD may increase risk for ovarian cancer
September 6, 2019: Healio – Symptoms of PTSD appeared associated with increased risk for ovarian cancer, especially among premenopausal women, according to study results published in Cancer Research. Read more,

Establishing Medical Fitness is the First Step in Treating Patients with Advanced Ovarian Cancer
August 26, 2019: Oncology Nursing News – Before considering intraperitoneal (IP) chemotherapy or dose-dense chemotherapy for a patient with newly diagnosed advanced ovarian cancer, their fitness should be established, said Jessica L. Berger, MD, as both approaches carry more toxicity than that of a standard weekly intravenous (IV) approach. Read more.

Case Review: Ovarian Cancer and the Initial Treatment Options
July 30, 2019: Targeted Oncology – Benedict Benigno, MD, discusses the case and treatment plan for a 58-year-old woman diagnosed with ovarian cancer. Read more.

Black Women With Cervical Cancer Less Likely to Receive Brachytherapy
July 29, 2019: Cancer Therapy Advisor – Black women with cervical cancer were less likely to receive brachytherapy and had poorer survival, suggesting brachytherapy may mediate survival outcomes. Read more.

Niraparib induces responses in late-line, BRCA-negative ovarian cancer
July 26, 2019: Healio – Niraparib demonstrated clinically relevant activity among women with heavily pretreated ovarian cancer, particularly those with homologous recombination deficiency-positive, platinum-sensitive disease, according to findings from the phase 2 QUADRA study published in The Lancet Oncology. Read more.

MD Anderson explains how to treat genetic mutations
July 24, 2019: KHOU – Dr. Pamela Soliman, Gynecologic Oncologist with MD Anderson Cancer Center, explains how to treat genetic mutations. Patient Yvonne Tate also shares her treatment story. Read more.

Collaborative Project Aims to Improve Care for Advanced Ovarian Cancer Patients
July 24, 2019: Ovarian Cancer News Today – A new collaborative project seeks to help ovarian cancer programs better understand and remove impediments to optimal care for patients with advanced epithelial disease. Called “Barriers to Quality Care in Ovarian Cancer,” the effort will be led by the Association of Community Cancer Centers (ACCC), along with AstraZeneca and Merck. Read more.

Ribociclib-Letrozole Regimen Tested in Ovarian, Endometrial Cancer
July 23, 2019: CancerNetwork – A phase II study found that the combination of ribociclib and letrozole showed promising activity in patients with estrogen receptor-positive ovarian cancer and endometrial cancer. The most benefit was observed in low-grade serous ovarian cancers. Read more.

Not Just Doctor’s Helpers: NPs and PAs Are Leaders in Cancer Care
July 23, 2019: Oncology Nursing News – When people picture the leaders of their cancer care, many may first think of oncologists or physicians. However, according to a recent study published in the Journal of the American Geriatrics Society, nurse practitioners actually comprised the largest group of providers for Medicare beneficiaries who received ambulatory care for any solid or hematologic malignancy. Read more.

Personalized Medicine Is the New Frontier in Ovarian Cancer
July 20, 2019: Oncology Nursing News – As new therapies such as PARP inhibitors have improved survival in patients with ovarian cancer, molecular testing is becoming more important, according to Jubilee Brown, MD. Read more.

Ontario study: Women undergoing minimally invasive procedures for early-stage cervical cancer had double the rates of death, recurrence
July 19, 2019: Cancer Letter – The population-based study, which included 958 cervical cancer patients who underwent minimally invasive between 2006 and 2017 in Ontario was designed to determine whether minimally invasive surgery is associated with adverse oncologic outcomes in cervical cancer patients. Read more.

Training for the Future: A Day in the Life of a Surgical Fellow
July 18, 2019: MSKCC – Emeline Aviki is a third-year gynecologic oncology fellow at MSK who is receiving advanced training in her field. Take a look inside her day. Read more.

US researchers study rucaparib in endometrial cancer patients
July 12, 2019: A research team at the University of Colorado Cancer Center (CU Cancer Center) in the US is set to lead a new clinical trial assessing poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib for the treatment of patients with endometrial cancer. Read more.

Doubled Risk of Death After MIS for Cervical Cancer: ‘Disturbing’
July 11, 2019: Medscape – Another blow has been dealt for minimally invasive surgery (MIS) in patients with cervical cancer — this time by Canadian researchers. Read more.

The cost of ’embarrassment’ when it comes to cervical cancer test
July 11, 2019: Sydney Morning Herald – According to a new survey from the Australian Cervical Cancer Foundation (ACCF), more than a quarter of Australian women say they are reluctant to book the Cervical Screening Test (CST, previously known as the Pap or smear test), with embarrassment or awkwardness around the procedure a major factor. Read more.

2 FOR 1 Smear tests could detect ovarian AND cervical cancer – as lack of ‘good’ vaginal bacteria ‘increases risk of deadly disease’
July 10, 2019: Sun – A drop in the number of lactobacilli present in the vagina significantly increased the risk of ovarian cancer, a new study found. Read more.

The Case for Tumor and Germline Testing in Endometrial Cancer Patients
June 27, 2019: CancerNetwork – A new study reinforces the need for universal mismatch repair (MMR) protein immunohistochemistry (IHC) screening of tumors from endometrial cancer patients, as well as germline genetic testing in accordance with the guidelines. Read more.

Breaking New Ground in the Treatment of Advanced Endometrial Cancer
June 19, 2019: CancerNetwork – In this interview, ONCOLOGY spoke with Vicky Makker, MD, a medical oncologist who treats patients with gynecologic cancers, including cervical, ovarian, and uterine tumors, about these options, as well as emerging combination therapies that are currently being evaluated in clinical trials. Read more.

Research Shows How Talc Powder May Change Ovarian Cancer Cells
June 18, 2019: Cancer Therapy Advisor –  In new research that was presented at the 2019 Annual Meeting of the Society of Gynecologic Oncology, Honolulu, Hawaii, Dr Saed’s team showed a link between talc and inflammation in normal and ovarian cancer cells. Read more.

After-cancer care: dealing with the long-term effects of cancer treatment
June 12, 2019: The Irish Times – Australian professor in Dublin to discuss infertility, early menopause and sexual problems. Read more.

Minimally invasive surgery linked to higher recurrence risk in early cervical cancer
June 7, 2019: Healio – Women who underwent minimally invasive surgery for early-stage cervical cancer demonstrated higher odds of recurrence than women who underwent open surgery, according to results of a multicenter retrospective study presented at ASCO Annual Meeting. Read more.

Olaparib prolongs PFS vs. chemotherapy in BRCA-mutated, platinum-sensitive ovarian cancer
June 7, 2019: Healio – Olaparib monotherapy significantly improved overall response rates and PFS, with no new safety signals, compared with nonplatinum chemotherapy among women with germline BRCA-mutated, platinum-sensitive relapsed ovarian cancer, according to results of the randomized phase 3 SOLO3 study presented at ASCO Annual Meeting. Read more.

Cervical Cancer During Pregnancy, Though Serious, is Highly Treatable According to New Research Review
June 4, 2019: News Wise – Over the years and with the publication of new studies, the treatment strategy has gradually changed to a more conservative treatment, particularly for patients in second or third trimester with early stage cancer. Read more.

Combo Therapy More Than Doubled PFS in Platinum-Sensitive Recurrent Ovarian Cancer
June 4, 2019: Cancer Network – The combination of the PARP inhibitor niraparib plus bevacizumab significantly improved progression-free survival in women with platinum-sensitive recurrent ovarian cancer. Read more.

Chemo-Free Doublet Significantly Improved PFS in Recurrent Ovarian Cancer
June 4, 2019: Targeted Oncology – The combination of niraparib (Zejula) and bevacizumab (Avastin) demonstrated a significant increase in progression-free survival (PFS) compared with niraparib alone in patients with platinum-sensitive recurrent ovarian cancer (PSROC), according to the results of the randomized ENGOT-OV24 trial. Read more.

Ovarian Cancer: Selecting Between Available PARPs
June 4, 2019:
Onc Live – Watch the video panel discussion.

Years of taking vitamin D appear to cut cancer death risk
June 4, 2019: Futurity – Vitamin D, if taken for at least three years, could help cancer patients live longer, say researchers. Read more.

NRG Oncology trial sets new standard regimen for women with uterine carcinosarcomas
June 2, 2019: Eureka Alert – The study concludes that among uterine cancer patients treatment with PC was not inferior to PI based on the primary objective overall survival (OS), and PC was associated with longer progression-free survival (PFS) outcomes when compared with PI. Read more.

Sexual Harassment in Training, Practice Reported by Two-Thirds of Gynecologic Oncologists
June 3, 2019: Targeted Oncology – Results from a survey conducted by the Society of Gynecologic Oncology (SGO) found that 70% of female and more than half of male gynecologic oncologists in the United States were victims of sexual harassment in either training or practice; and of those, only 10% said they reported their experiences. Read more.

FDA announces Expanded Access pilot program for oncology
June 3, 2019: Hem Onc Today – The FDA today announced a pilot project called OCE Project Facilitate aimed at allowing physicians to more easily navigate its Expanded Access program for investigational oncology treatments. Read more.

Tumor-infiltrating lymphocyte therapy appears safe, effective in melanoma, cervical cancer
June 2, 2019: Healio – Data from two trials evaluating the safety and efficacy of adoptive cell transfer with autologous tumor-infiltrating lymphocytes showed promising overall response rates for the treatment of advanced metastatic melanoma and cervical cancer, according to results presented at ASCO Annual Meeting. Read more.

5 Signs That Could Mean Ovarian Cancer–Early Stages Are Hard to Detect, Here’s How
May 27, 2019: The Epoch Times – Every year, roughly 21,000 people in the United States and 295,000 people worldwide are diagnosed with ovarian cancer. It’s the eighth-most common cancer for women globally, making up just under 4 percent of all cancer cases diagnosed in 2018. Read more.

Aggressive uterine cancer rising, particularly for black women
May 24, 2019: Axios – Women aged 30-70 — particularly black women — have been getting aggressive and deadly types of uterine cancer at higher rates in recent years, according to new research published by the National Cancer Institute earlier this week. Read more.

Deep Learning Model Can Predict Breast Cancer up to Five Years in Advance
May 24, 2019: Interesting Engineering – Researchers from MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) and Massachusetts General Hospital (MGH) have created a new deep-learning model that can improve the early detection of breast cancer. Read more.

Research sheds new light on the function of frequently mutated cancer protein
May 24, 2019: News Medical –  According to the study, published online in Science Advances, ARID1A plays a role in the spatial organization of the genome; therefore, its loss has broad effects on global gene expression. This finding adds critical information towards deciphering the molecular alterations associated with several cancer types and especially with ovarian cancer. Read more.

FDA Grants Novel TIL Therapy Breakthrough Therapy Designation for Advanced Cervical Cancer
May 24, 2019: Targeted Oncology – The FDA has granted a breakthrough therapy designation to novel tumor-infiltrating lymphocyte therapy LN-145 for the treatment of patients with recurrent, metastatic, or persistent cervical cancer who have progressed on or after chemotherapy. Read more.

Predicting breast cancer metastasis by cell behavior instead of genetics
May 20, 2019: Medical Xpress – The test measures two key cell behaviors that are required for metastasis to occur: cell motility, the measure of how capable cells are of traveling to distant sites within the body, and proliferation, which is how much they are multiplying. Read more.

Case Report: Molecular Detection of Endometrial Precancer Using a Targeted Gynecologic Cancer Liquid Biopsy
May 17, 2019: Clinical Oncology – By using uterine lavage fluid for analysis, researchers provided the first demonstration that future, tumor-specific mutations can be identified in an asymptomatic woman without clinical or pathologic evidence of cancer. Read more.

Assessing the Benefit of Trebananib in Advanced Ovarian Cancer
May 16, 2019: Cancer Network – The angiogenesis inhibitor trebananib failed to improve outcomes over placebo when combined with carboplatin and paclitaxel in patients with advanced ovarian cancer, according to a phase III trial. Read more.

FDA Lifts Partial Hold on AIM2CERV Trial of Investigational Immunotherapy Agent in Cervical Cancer
May 15, 2019: Targeted Oncology – The FDA has lifted the partial clinical hold placed on the phase III AIM2CERV trial (NCT02853604), which is evaluating axalimogene filolisbac (AXAL) for the treatment of patients with high-risk locally advanced cervical cancer, according to Advaxis, the developer of the investigational immunotherapy agent. Read more.

Vulval cancer: Woman undiagnosed for seven years
May 10, 2019: BBC – A County Down woman who has had surgery following vulval cancer is appealing to women to check themselves and be aware of changes in their genital area. Read more.

Research could lead to more precise diagnosis and treatment of ovarian cancer
May 8, 2019: Medical Xpress – Oncologists may soon have an accurate and inexpensive way of differentiating between types of ovarian cancer that will improve how patients are treated, thanks to findings from a national research study co-led out of the University of Alberta. Read more.

How Rwanda could be the first country to wipe out cervical cancer
May 7, 2019: Mosaic Science – The East African country’s campaign to end cervical cancer through the HPV vaccine has had to overcome cultural taboos and rumours about infertility – but it’s saving lives. Read more.

Pembrolizumab Provides Hope for PD-L1–Positive Cervical Cancer Patients
May 7, 2019: Cancer Network – Single-agent pembrolizumab showed durable clinical activity in patients with previously treated advanced cervical cancer enrolled on the phase II KEYNOTE-158 basket trial, and activity was higher among patients with programmed death-ligand 1 (PD-L1)–positive tumors (combined positive score [CPS] ≥1). The interim results were published in the Journal of Clinical Oncology. Read more.

Study Finds Synergism With Olaparib/Neratinib Combo in HER2+ Uterine Serous Carcinoma
May 6, 2019: Targeted Oncology – In new preclinical data, the combination of the PARP inhibitor olaparib (Lynparza) and the pan-HER TKI neratinib (Nerlynx) was found to be highly synergistic in HER2-positive uterine serous carcinoma, according to lead study author Ghanshyam Yadav, MD. Read more.

Screening for Human Papillomavirus in a Low- and Middle-Income Country
May 3, 2019: Journal of Global Oncology – This work demonstrates a deployable protocol for HPV screening in low- and middle-income countries with limited resources to perform cytopathology assessment of Pap smears. Read the article.

Study shows ovarian cancer survival increase
May 3, 2019: Medical Xpress – A gynecologic oncologist at the Stephenson Cancer Center at OU Medicine was a national leader of a newly published research study that reveals good news for women with ovarian cancer—longer survival times plus a treatment option that causes fewer difficult side effects. Read more.

Changes in the metabolism of normal cells promotes the metastasis of ovarian cancer cells
May 1, 2019: Science Daily – A systematic examination of the tumor and the tissue surrounding it — particularly normal cells in that tissue, called fibroblasts — has revealed a new treatment target that could potentially prevent the rapid dissemination and poor prognosis associated with high-grade serous carcinoma (HGSC), a tumor type that primarily originates in the fallopian tubes or ovaries and spreads throughout the abdominal cavity. Read more.

Women with Ovarian Cancer Less Likely to Alert Providers As Symptoms Worsen
April 18, 2019: Oncology Nursing News – The more severe their symptoms, the less likely women with ovarian cancer are to report the discomforts to their oncologists, a study found. Read more.

Don’t Count on 23andMe to Detect Most Breast Cancer Risks, Study Warns
April 16, 2019: New York Times – A study of 100,000 people released earlier this month suggested that this experience could be widespread. Nearly 90 percent of participants who carried a BRCA mutation would have been missed by 23andMe’s test, geneticists found. Read more.

Positive results of regional perfusion chemotherapy for progressive and refractory ovarian cancer made public today
April 16, 2019: EIN Presswire -Hypoxic abdominal perfusion for progressive and refractory ovarian cancer is an effective therapy offering comparably long survival at good quality of life. Read more.

Urinary HPV DNA Testing Can Reach Additional Women
April 14, 2019: Precision Vaccinations – A new study evaluated an alternative HPV cervical cancer test for women who are reluctant to have a Pap Smear. Read more.

Language on Social Media Reveals Concerns of Patients with Ovarian Cancer
April 14, 2019: Oncology Nursing News – The language used on social media can reveal important clues about the perspectives, values, and needs of patients and caregivers affected by ovarian cancer, and a recent study of this data should be the first of many, according to a research team whose results were presented at the ONS 44th Annual Congress. Read more.

The HPV vaccine is important for preteens and teenagers. What about older women?
April 13, 2019: Washington Post – ‘Is Gardasil 9 right for me?” my patient asked during a recent office visit. Read more.

HPV rates are increasing among women under 40
April 12th, 2019: Futurity – Human papillomavirus infection rates are increasing in women born after 1980 who did not receive the HPV vaccine, research finds. Read more.

Socioeconomic barriers limit successful cervical cancer screening
April 12, 2019: Healio – Screening for cervical cancer has been a “great success,” according to a speaker at the American College of Physicians Internal Medicine Meeting. However, socioeconomic barriers prevent all women from gaining equal access to screening. Read more.

Saliva Tests Can Identify HPV16
April 11, 2019: Precision Vaccinations – Oral rinse samples have been found to contain reliable and reproducible HPV DNA data. Read more.

Loss of a DNA repair system creates a unique vulnerability in many cancer types
April 11, 2019: Science Daily –  Cancer cells that cannot repair a certain form of DNA mutation become strongly dependent on single enzyme to survive, creating a new potential opportunity for drug development. Read more.

What’s new in biomarker testing for ovarian cancer
April 10, 2019: Contemporary OB/GYN – Advances in biomarker discovery have led to several FDA-approved tests superior to CA125 in preoperative evaluation of women with a pelvic mass. Read more.

Ovarian cancer patients undertested for mutations that could guide clinical care
April 10, 2019: MD Linx – Fewer than a quarter of breast cancer patients and a third of ovarian cancer patients diagnosed between 2013 and 2014 in two states underwent genetic testing for cancer-associated mutations, according to a study by researchers at the Stanford University School of Medicine and several other organizations. Read more.

Does your gender influence your clinical decision-making?
April 09, 2019: MD Linx – Have you ever wondered whether male or female physicians take different approaches to patient care? Well, this certainly seems to be the case. Female physicians tend to take a more robust approach when deducing patient care, according to a recent study published in Gynecologic Oncology Reports. Read more.

3D ultrasound gives clinicians clearer picture to treat gynecological cancer
April 9, 2019: Eureka Alert – By transforming a conventional ultrasound probe, already found in most clinics, the technology can provide a 360-degree, three-dimensional view of surgical tools and surrounding tissue and organs. Read more.

Coleman Highlights Benefit With Maintenance Rucaparib Across Ovarian Cancer Subgroups
April 8, 2019: Targeted Oncology – In findings from the phase III ARIEL3 trial, maintenance therapy with the PARP inhibitor rucaparib (Rubraca) demonstrated an improvement in progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer. Further analyses presented during the 2019 SGO Annual Meeting showed that this therapy is safe and effective across all subgroups of patients, regardless of age. Read more.

Cancer vaccine shows promising results in Lynch syndrome
April 8, 2019: Drug Target Review – Vaccination with as few as four tumour antigens generated antigen-specific responses, reduced intestinal tumours, and improved survival in a mouse model of Lynch syndrome, suggesting that it may be possible to develop a cancer preventive vaccine for patients with Lynch syndrome, according to data presented at the AACR Annual Meeting 2019 last week. Read more.

More Research is Needed to Prevent Late-Stage Diagnosis of Ovarian Cancer
April 8, 2019: Cure – Of the many challenges facing patients with ovarian cancer, one of the biggest is late-stage or delayed diagnosis due to the disease’s subtle signs and symptoms, according to Paula Anastasia RN, MN, AOCN. Read more.

Do Breast Cancer Patients Skip Follow-Up?
April 7, 2019: MedPage Today – Within the 5 years following a diagnosis for stage I or II breast cancer, 21% of patients stop seeing physicians for follow-up care, according to a study in the Journal of Oncology Practice. Read more.

New HPV Vaccine May Be Able to Treat Existing Infections and Cure Precancers
April 5, 2019: Health Central – In a clinical trial, researchers used the immune-based therapeutic injection on precancerous cells in the cervix, and one-third of the women treated were completely cured of the precancer and the underlying HPV infection. Read more.

Updates to Ovarian Cancer Guidelines Emphasize Importance of Germline, Somatic Testing
April 5, 2019: Targeted Oncology – Several bevacizumab (Avastin) combinations and the use of 3 FDA-approved PARP inhibitors have been introduced in the National Comprehensive Cancer Network (NCCN) guidelines for the treatment of patients with ovarian cancer. Based on these updates, the use of germline and somatic testing has become increasingly important in making treatment decisions for these patients. Read more.

Experimental therapy completely clears HPV in one-third of cervical cancer precursors
April 4, 2019: Medical Xpress – A potential new immune-based therapy to treat precancers in the cervix completely eliminated both the lesion and the underlying HPV infection in a third of women enrolled in a clinical trial. Read more.

Older women have the highest risk of dying from cervical cancer
April 3, 2019: Science Daily – New research shows that women aged 65 and older have a higher risk of dying from cervical cancer than previously thought — although this age group is not covered by the Danish screening program. Read more.

Study: The Pill May Protect Against Ovarian Cancer
April 3, 2019: WebMD – The protection that birth control pills offer against ovarian cancer is strongest with the most aggressive forms of the disease, a new study says. Read more.

Immune response worsens outcomes for African American patients with ovarian cancer, USA Health study finds
April 2, 2019: Alabama News Center – African American patients with advanced ovarian cancer were found to have a pre-existing immune response linked to worse survival rates compared with their white counterparts, according to research led by Dr. Rodney Rocconi, a gynecologic oncologist and interim director of the USA Health Mitchell Cancer Institute. Read more.

How Surgical Robot Assistants Are Becoming A Reality In Indian Hospitals And Healthcare Sector
April 2, 2019:
Analytics India Magazine – According to a 2018 study by a leading job portal, India witnessed a spike in the number of job seekers in the field of robotics by 186 per cent, whereas, job postings in the segment stood at 191 per cent. Read more.

ePRO Tool Improves Symptom Management in an Outpatient Gynecologic Cancer Clinic
April 1, 2019: Oncology Nurse Advisor – The Patient-Reported Outcomes Measurement Information System (PROMIS) Network, funded by the National Institutes of Health (NIH), was developed to be a collaborative effort to advance and standardize measurement of health-related quality of life (HRQOL) in clinical practice. Read more.

Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer
April 1, 2019: MD Linx – In this phase II study, researchers examined the antitumor activity of nintedanib, a tyrosine kinase inhibitor of VEGF, FGF, and PDGF receptors, in bevacizumab-resistant recurrent epithelial ovarian cancer (EOC), tubal, and peritoneal cancer. Read more.

Gynecology Experts Reflect on Precision Medicine Highlights From SGO Annual Meeting
March 29, 2019: Targeted Oncology -A common theme evident among the abstracts presented during the 2019 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, held earlier this month in Honolulu, Hawaii, was matching the right treatment to the right patient at the right time, said Shannon Westin, MD, which is a foundation of precision medicine. Read more.

FDA proposes mammogram changes for first time in 20 years to identify breast cancer early
March 28, 2019: USA Today – The U.S. Food and Drug Administration proposed new rules Wednesday that will require mammogram centers to tell women more about how dense breast tissue can affect their health and increase their cancer risk. Read more.

Phase III Trial Launches to Investigate TTFields With Paclitaxel in Recurrent Ovarian Cancer
March 26, 2019: Targeted Oncology – A pivotal phase III INNOVATE-3 trial investigating the efficacy of tumor-treating fields (TTFields; Optune) combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer has been initiated, according to Novocure, the company developing the device. Read more.

Racial Disparities in Hospice Enrollment Persist in Ovarian Cancer
March 25, 2019: Cancer Network – Though many elderly patients with ovarian cancer enroll in hospice care, a substantial proportion subsequently unenroll and die without hospice, according to a new study. Black patients are more likely to unenroll than white patients. Read more.

Low White Blood Cell Count May Help Predict Some Ovarian Cancer Outcomes
March 22, 2019: Ovarian Cancer News Today – A reduced number of lymphocytes — one of the main types of immune cells — in advanced ovarian cancer patients before treatment is linked with a higher risk of disease worsening and shorter overall survival, according to a South Korean study. Read more.

Immunotherapy Improves Prognosis for Recurrent Ovarian Cancer Patients
March 21, 2019: Precision Vaccinations – Dendritic cell-based immunotherapy uses the patient’s own immune system to combat cancer and offers long-lasting antitumor immunity. Read more.

Cervical screening: DIY smear test could be ‘game-changer’
March 21, 2019: BBC News – Women are to be offered the chance to carry out smear tests at home in a bid to cut the rates of cervical cancer. Read more.

Evaluating Chemotherapy Plus Adjuvant Radiation Therapy for Vulvar Cancer
March 18, 2019: Cancer Therapy Advisor – Results of this retrospective study showed that adjuvant chemoradiation (CRT) did not significantly improve overall survival (OS) compared with adjuvant radiation therapy (RT) alone in women with squamous cell carcinoma of the vulva. Read more.

SGO 2019: Less Worry, More Symptoms and Regret With Risk-Reducing Salpingo-Oophorectomy
March 18, 2019: Cancer Network – Women at increased risked for hereditary ovarian cancer who underwent risk-reducing salpingo-oophorectomy experienced less worry but worse menopausal symptoms and more regret compared with those who underwent salpingectomy with delayed oophorectomy, the Women Choosing Surgical Prevention (WISP) trial reported ( Identifier: NCT02760849). Read more.

Carboplatin Desensitization Associated With Improved Overall Survival in Recurrent Ovarian Cancer
March 18, 2019: Cancer Therapy Advisor -Results from a retrospective study of patients with recurrent ovarian cancer treated with carboplatin chemotherapy showed that overall survival (OS) was significantly longer for patients treated with a carboplatin desensitization protocol (due to carboplatin hypersensitivity) compared with those who did not exhibit carboplatin hypersensitivity reactions. Read more.

Racial Differences in Immune Escape Mechanisms of Ovarian Cancer
March 18, 2019: Cancer Therapy Advisor – RNA expression of 5 genes involved in the indoleamine 2.3-dioxygenase (IDO) pathway, a marker of escape from immune control, was significantly upregulated in black patients with advanced ovarian cancer compared with matched white patients (P <.01). These findings were presented at the SGO 50th Annual Meeting on Women’s Cancer. Read more.

Individualized Dosing Regimen Reduces Side Effects in Ovarian Cancer Maintenance Therapy
March 18, 2019: Cure – Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose, according to a recent analysis of the ongoing ENGOT-OV26/PRIMA study. Read more.

Brachytherapy improves survival in advanced cervical cancer, but racial disparities remain
March 17, 2019: Healio – Black women —who have the highest cervical cancer mortality — are significantly less likely than white women to receive the boost as part of treatment. Read more.

PFS Increased With Niraparib Without Symptoms or Toxicity in Ovarian Cancer
March 17, 2019: Targeted Oncology – Treatment with maintenance niraparib (Zejula) led to extended progression-free survival (PFS) time in patients with recurrent ovarian cancer without the patients experiencing symptoms or toxicity compared with placebo, according to results of an analysis from the phase III ENGOT-OV16/NOVA trial. Read more.

Conservatively Managing Ovarian Tumors
March 10, 2019: ASCO Post – In an interim analysis of a prospective cohort study (IOTA5) reported in The Lancet Oncology, Wouter Froyman, MD, and colleagues found that the risk of malignancy and acute complications is low when adnexal masses with benign ultrasound findings are managed conservatively. Read more.

Moving Away From IP Chemotherapy in Advanced Ovarian Cancer
February 28, 2019: OncLive – Dr. Bradley Monk discusses the evolution of treatment of women with advanced-stage epithelial ovarian cancer. Read the article.

Lymphadenectomy fails to extend survival, linked to more complications in ovarian cancer
February 27, 2019: Healio – Systematic pelvic and paraaortic lymphadenectomy failed to improve survival among women with advanced ovarian cancer who underwent macroscopically complete resection and had normal lymph nodes before and during surgery, according to results from the randomized LION trial published in The New England Journal of Medicine. Read more.

New Grant Award Supports Research on Early Detection of Ovarian Cancer
February 26, 2019: Georgia Tech – Promising research toward what could become the first simple and accurate test for the early detection of ovarian cancer could be validated – and expanded – thanks to a significant grant from the Prevent Cancer Foundation. Read more.

Cervical cancer study suggests ‘global elimination is within reach’
February 26, 2019:  Healio – A rapid scale-up of HPV vaccination and screening could effectively eliminate cervical cancer as a major public health problem in most countries by 2100, according to a modelling study published in Lancet Oncology. Read more.

Patients’ HIV status should not impact their cancer care
February 25, 2019: Medical Xpress – New articles published in Cancer, a peer-reviewed journal of the American Cancer Society, note that there is no medical justification to deny optimal cancer therapy to individuals with HIV. Read more.

Could Conservative Management of Adnexal Masses Lead to Ovarian Cancer?
February 20, 2019: Cancer Network – “Our results suggest that the risk of malignancy and acute complications is low if adnexal masses with benign ultrasound morphology are managed conservatively,” the authors concluded. Read more.

Compound Could Help Treat Ovarian Cancer
February 20, 2019: Technology Networks – In the paper, published in the Journal of the American Chemical Society, scientists screened new compounds made in the lab against a “panel” of cancers that were sensitive and resistant to standard cancer therapy. Read more.

Breast Cancer Treatments Could Be Used for Rare Ovarian Cancer, Study Suggests
February 20, 2019: Ovarian Cancer News Today – Medications currently approved to treat some kinds of breast cancer — generally called CDK4/6 inhibitors — could be re-purposed to treat a rare type of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a study suggests. Read more.

Losartan May Improve Ovarian Cancer Treatment, Study Finds
February 11, 2019: Ovarian Cancer News Today – Losartan, a medicine used for treating high blood pressure, might improve ovarian cancer treatment by making it easier for chemotherapy drugs to get to tumor cells, a study found. Read more.

Minimally invasive cervical cancer surgery may promote disease recurrence; professionals urge patience
February 10, 2019: HemOnc Today spoke with gynecologic oncologists and surgeons about the results of these two studies, whether the data should have an immediate impact on clinical practice, what questions are left unanswered, and how surgeons should treat their patients before further conclusions are drawn. Read more.

Japanese study finds concerning trends in cervical cancer and treatment response
February 7, 2019: Medical Xpress –  Cervical cancer rates can be greatly reduced through preventive measures against the human papillomavirus (HPV) along with proactive cancer screening. Japan may be showing how ignoring that knowledge could prove hazardous, as it is the only advanced economy in which the cervical cancer rate is increasing. Read more.

Fallopian Tube Cancer Market Growth Opportunities by Regions, Scope, Key Players, Type and Application; Trend Forecast 2026
February 7, 2019: World Analytics – Key Market Dynamics of the Fallopian Tube Cancer Market Market report provides thorough forecasts on the latest market trends, development patterns, and research methodologies. Read more.

Where does Immune Checkpoint Inhibition fit in Advanced Ovarian Cancer Treatment
January 29, 2019: Cancer Network – The new study involved an expansion cohort from the phase I JAVELIN Solid Tumor trial, including a total of 125 patients with advanced ovarian cancer who had previously received chemotherapy including a platinum agent. Patients were treated with the anti–programmed death ligand 1 (PD-L1) agent avelumab at a dose of 10 mg/kg every 2 weeks. Read more.

Patients With Gynecologic Cancers Want to Discuss Sexual Health
January 25, 2019: Cure Today – Vaginal dryness, vaginal irritation, vaginal scar tissue, yeast infections and infertility are a few effects that patients can experience, all of which can affect intimate relations. However, these concerns are not always addressed by health care providers. Read more.

Avelumab demonstrates antitumor activity in ovarian cancer
January 24, 2019: Healio – Avelumab demonstrated antitumor activity and safety among heavily pretreated patients with recurrent or refractory ovarian cancer, according to results from the JAVELIN solid tumor study published in JAMA Oncology. Read more.

FDA places partial hold on phase 3 trial of axalimogene filolisbac for cervical cancer
January 24, 2019: HemOnc Today – The FDA placed a partial clinical hold on the ongoing randomized, double-blind, placebo-controlled AIM2CERV trial, which is evaluating axalimogene filolisbac in high-risk, locally advanced cervical cancer. Read more.

Scientists Discover New Potential Way To Stop Breast Cancer Spreading
January 21, 2019: Forbes – A new study published today in the journal Nature Cell Biology has uncovered a new way by which cells that have broken away from the original tumor (disseminated tumor cells) may hide in other parts of the body, evading therapy designed to eliminate them before they can grow into metastatic tumors. Read more.

Why Is Uterine Cancer on the Rise?
January 16, 2019: US News – Research indicates that the increase in obesity in the U.S. can be correlated with the rise in uterine cancer deaths. Read more.

Can AI Outperform Doctors at Detecting Cervical Cancer?
January 18, 2019: Cancer Network – A computer algorithm was able to accurately analyze digital images of cervical screenings and identify precancerous changes that required further medical follow-up, a new study showed. The new approach, called automated visual evaluation, has the potential to change point-of-care cervical screening. Read more.

Five updates in cervical cancer
January 11, 2019: Healio – Here are 5 articles related to advances in cervical cancer detection and treatment, new data on the role of HPV positivity, and the persistent underuse of HPV vaccination and cervical cancer screening. Read more.

Trial Failure Still Yields Insights for Uterine Leiomyosarcoma
January 10, 2019: Cancer Network – Acknowledging the small study population, Chapman-Davis concluded that the trial adds to the existing literature that supports observation as the standard of care in the adjuvant setting for patients with high-grade uterine leiomyosarcoma. Read more.

OncoSec and Gynecologic Oncology Group (GOG) Foundation, Inc. to Conduct a Pivotal Study of TAVO™ with Standard of Care KEYTRUDA® for Treatment of Late Stage Cervical Cancer
January 7, 2019: PRNewswire – In this registration-directed clinical trial, OncoSec and GOG will evaluate the combination of TAVO and commercially available KEYTRUDA with the goal of achieving a clinically meaningful response rate greater than what has already been demonstrated with KEYTRUDA alone (14%). Read more.

Exploring the feasibility of using mobile phones to improve the management of clients with cervical cancer precursor lesions
January 7, 2019: BMC Women’s Health – Cancer screening programs hold much potential for reducing the cervical cancer disease burden in developing countries. The aim of this study was to determine the feasibility of mobile health (mHealth) phone technology to improve management and follow-up of clients with cervical cancer precursor lesions. Read more.

Women With Select Subtypes of HPV at Higher Risk for Developing High-Grade Cervical Cancer
January 4, 2019: Targeted Oncology – The nested case-control Swedish study, published in Cancer, found that the presence of specific subtypes of HPV, namely HPV-16 and -18, were associated with a higher risk of developing high-grade cervical intraepithelial neoplasia (CIN) in women under the age of 30. Read more.

Avelumab fails to extend PFS in ovarian cancer
January 2, 2019: Healio – A randomized phase 3 trial designed to evaluate avelumab for women with previously untreated advanced ovarian cancer failed to achieve its primary endpoint of PFS. Read more.

Claim CME for IGCS2019

IGCS 2019 Meeting Participants:

On behalf of the Global Meeting of the International Gynecologic Cancer Society, we wish to thank you for your participation at IGCS 2019 held in Rio de Janeiro, Brazil on September 19 – 21 2019. We were delighted to host 1,018 participants from more than 73 different countries who found the scientific program both stimulating and enriching. We are very grateful that you took time out of your busy schedule to participate.

The CME/CPD certificate will be available after completing the online evaluation and credit claiming procedure. The process takes about 5 minutes. We thank you for your feedback as it is an important part of CME/CPD accreditation and helps improve future educational offerings.

Before October 19, 2019:

  • Complete the anonymous online evaluation
  • Complete the credit claim form and submit
  • The CME/CPD certificate will be available for download and/or print for your personal records.

Thank you for your time and participation. Please contact us with any questions.

With best regards,
IGCS 2019 Meeting Secretariat

Live Stream Educational Webinar Sept 6

IGCS Live Stream Gynecologic Cancer Update

Please join us for the first-ever live streaming offering from the International Gynecologic Cancer Society! This educational webinar provides our global audience with state-of-the-art education and opportunities to interact with expert faculty in a format you can join from the comfort of your home or office.

This is a free, live-streaming educational event created by the IGCS Education Committee.

Access the Live Broadcast Here.

Friday, September 6, 2019

6:00 AM – 9:00 AM (Chicago / Mexico)
7:00 AM – 10:00 AM  (New York / Colombia / Peru)
8:00 AM – 11:00 PM (Brazil / Argentina)
12:00 PM – 3:00 PM (United Kingdom)
1:00 PM – 4:00 PM (Europe / South Africa)

2:00 PM – 5:00 PM (Belarus / Turkey / Kenya)
4:30 PM – 7:30 PM (India)
7:00 PM – 10:00 PM (China)
8:00 PM – 11:00 PM (Tokyo)
9:00 PM – 12:00 AM (Sydney)

Check the event start time in your city.

View the Webinar Schedule.

Expert Speakers

R. Wendel Naumann, MD
Levine Cancer Institute
Charlotte, NC
Angeles Alvarez Secord, MD
Duke University
Durham, NC
Matthew Powell, MD
Washington University
St. Louis, MO
Thomas Herzog, MD
University of Cincinnati Cancer Institute
Cincinnati, OH

Robert Coleman, MD
University of Texas, MD Anderson Cancer Center
Houston, Texas
Jubilee Brown, MD
Levine Cancer Institute
Charlotte, NC
Ginger Gardner, MD
Memorial Sloan-Kettering Cancer Center
New York, NY
Ritu Salani, MD
The Ohio State University
Columbus, OH

This webinar is supported by:

2019 Award Recipients

It is important to acknowledge the exemplary work being done in the gynecologic cancer community on a global level.

This year, we are happy to announce two new award categories that will be given at the 2019 IGCS Annual Global Meeting in Rio: Outstanding Achievement in Gynecologic Surgery and the Distinguished Advocacy Awards.

Since the 2016 IGCS meeting in Lisbon, the recognition and awards program has been expanded to include new categories. In 2016 and 2018 we celebrated those who have displayed excellence in innovation and in teaching, those who have conducted humanitarian efforts, and those who have achieved community advancement in areas of the globe that need the most attention.

Awards do not only acknowledge success; they recognize many other qualities: courage, ability, effort and, above all, excellence. These individuals truly deserve worldwide recognition for their contributions. They motivate us all to imagine what we are capable of, to inspire us to undertake ambitious projects and to strive to continually do better.

It is my honor to announce the 2019 IGCS Award Recipients:

Lifetime Achievement Award

Sergio Pecorelli, MD, PhD (Italy)
For his dedication to pelvic cancer surgery, with original contributions in the field of conservative surgery for ovarian neoplasms, this award recognizes excellence, outstanding service and accomplishment spanning a career in gynecologic oncology.



Excellence in Teaching Award

Groesbeck Parham, MD (USA/Zambia)
For his leadership in the CIDRZ Cervical Cancer Prevention Program and extensive collaborative efforts to raise awareness of women’s health issues in sub-Saharan Africa, this award recognizes a deep commitment and dedication to gynecologic oncology, exemplifying the core components of teaching and education.



Outstanding Achievement in Gynecologic Surgery

Manuel Penalver, MD (USA)
For his instrumental role in a medical breakthrough known as the Miami Pouch operation which allows women who have lost their bladder to recurring cancer to enjoy a better quality of life,this award recognizes outstanding surgical achievements and contributions to the field of gynecologic oncology.



Community Advancement in Resource-Limited Settings

Jorge Saad Souen, MD (Brazil)
For his work in Brazil to promote early detection, prevention and optimal treatment of women affected by gynecologic cancers, this award recognizes steadfast dedication to improving care in local communities through leadership and facilitation of advanced medical education and training in resource-limited settings.



Distinguished Advocacy Award

Venus Ginés (USA)
For steadfast advocacy in Latino and other medically underserved communities throughout the continental United States, Puerto Rico, and the Dominican Republic, including training more than 3,000 Promotores (Community Health Workers) in Texas alone.



Miho Katagi (Japan)
For outstanding advocacy in Japan, including co-founding SMILEY—the first ovarian cancer patient support group in Japan—and successfully lobbying to improve the speed with which drugs for ovarian cancer and other diseases are approved for patient use.



Benda Kithaka (Kenya) & Women4Cancer Early Detection & Treatment
For dedicated advocacy in Kenya through Women4Cancer Early Detection & Treatment, which has provided cancer education outreach to over 45,000 Kenyans and free cervical and breast cancer screening—with follow-up facilitation to treatment—for over 7,500 rural women




These outstanding individuals will be recognized at the upcoming Annual Global Meeting of the International Gynecologic Cancer Society, September 19-21 in Rio de Janeiro, Brazil.

Please join me in congratulating them on their achievements!

Roberto Angioli, MD
2018-2020 IGCS President